| Samuel Harms, MD | |
|
1000 E 1st St, Suite 404, Duluth, MN 55805-2297 | |
| (218) 722-5579 | |
| (218) 625-2709 |
| Full Name | Samuel Harms |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 18 Years |
| Location | 1000 E 1st St, Duluth, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447397799 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center-mesabi/ Mesaba Clinics | Hibbing, MN | Hospital |
| Ely Bloomenson Community Hospital | Ely, MN | Hospital |
| St Lukes Hospital | Duluth, MN | Hospital |
| Lake View Memorial Hospital | Two harbors, MN | Hospital |
| North Shore Health | Grand marais, MN | Hospital |
| Heritage Manor | Chisholm, MN | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopedic Associates Of Duluth Pa | 1951294065 | 33 |
| Range Regional Health Services | 8022920024 | 121 |
News Archive
News outlets sort through the players in this drama to find winners and losers - as well as how some lawmakers and advocates will move forward.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.
Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.
Unless you find more realistic ways of paying for the promises included in the bill, you are simply setting up the public for more frustration - and yourselves for a political backlash (David Broder, 11/13).
The technique, pioneered by the University of Kent, is funded by the Toronto-based company, Ophthalmic Technology Inc (OTI). The University's Applied Optics Group is currently working with university hospitals in New York (USA), Osaka (Japan), Asahikawa (Japan), Amsterdam (Netherlands) and Milan (Italy) to carry out preliminary clinical trials.
› Verified 4 days ago
| Entity Name | Range Regional Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669569265 PECOS PAC ID: 8022920024 Enrollment ID: O20031110000095 |
News Archive
News outlets sort through the players in this drama to find winners and losers - as well as how some lawmakers and advocates will move forward.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.
Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.
Unless you find more realistic ways of paying for the promises included in the bill, you are simply setting up the public for more frustration - and yourselves for a political backlash (David Broder, 11/13).
The technique, pioneered by the University of Kent, is funded by the Toronto-based company, Ophthalmic Technology Inc (OTI). The University's Applied Optics Group is currently working with university hospitals in New York (USA), Osaka (Japan), Asahikawa (Japan), Amsterdam (Netherlands) and Milan (Italy) to carry out preliminary clinical trials.
› Verified 4 days ago
| Entity Name | Ely-bloomenson Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770542904 PECOS PAC ID: 0042200040 Enrollment ID: O20040513000074 |
News Archive
News outlets sort through the players in this drama to find winners and losers - as well as how some lawmakers and advocates will move forward.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.
Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.
Unless you find more realistic ways of paying for the promises included in the bill, you are simply setting up the public for more frustration - and yourselves for a political backlash (David Broder, 11/13).
The technique, pioneered by the University of Kent, is funded by the Toronto-based company, Ophthalmic Technology Inc (OTI). The University's Applied Optics Group is currently working with university hospitals in New York (USA), Osaka (Japan), Asahikawa (Japan), Amsterdam (Netherlands) and Milan (Italy) to carry out preliminary clinical trials.
› Verified 4 days ago
| Entity Name | Orthopedic Associates Of Duluth Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225033715 PECOS PAC ID: 1951294065 Enrollment ID: O20140617000407 |
News Archive
News outlets sort through the players in this drama to find winners and losers - as well as how some lawmakers and advocates will move forward.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.
Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.
Unless you find more realistic ways of paying for the promises included in the bill, you are simply setting up the public for more frustration - and yourselves for a political backlash (David Broder, 11/13).
The technique, pioneered by the University of Kent, is funded by the Toronto-based company, Ophthalmic Technology Inc (OTI). The University's Applied Optics Group is currently working with university hospitals in New York (USA), Osaka (Japan), Asahikawa (Japan), Amsterdam (Netherlands) and Milan (Italy) to carry out preliminary clinical trials.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samuel Harms, MD 10663 Montgomery Road, Cincinnati Sportsmedicine And Orthopaedic Center, Cincinnati, OH 45242-0001 Ph: (513) 347-9999 | Samuel Harms, MD 1000 E 1st St, Suite 404, Duluth, MN 55805-2297 Ph: (218) 722-5579 |
News Archive
News outlets sort through the players in this drama to find winners and losers - as well as how some lawmakers and advocates will move forward.
Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.
Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.
Unless you find more realistic ways of paying for the promises included in the bill, you are simply setting up the public for more frustration - and yourselves for a political backlash (David Broder, 11/13).
The technique, pioneered by the University of Kent, is funded by the Toronto-based company, Ophthalmic Technology Inc (OTI). The University's Applied Optics Group is currently working with university hospitals in New York (USA), Osaka (Japan), Asahikawa (Japan), Amsterdam (Netherlands) and Milan (Italy) to carry out preliminary clinical trials.
› Verified 4 days ago
Dr. Joel A Zamzow, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 E 1st St, Ste 400, Duluth, MN 55805 Phone: 218-722-5513 Fax: 218-722-6515 | |
Samuel C. Hoxie, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 400 East 3rd Street, Essentia Health Duluth Clinic, Duluth, MN 55805 Phone: 218-786-3520 | |
Glen H Rudolph, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 E 1st St Ste 404, Duluth, MN 55805 Phone: 218-722-5513 Fax: 218-722-6515 | |
Kathryn Elizabeth Huff, D.O. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 407 E 3rd St, Duluth, MN 55805 Phone: 218-786-4000 | |
William R Lundberg, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1012 E 2nd St Bldg A4th, Duluth, MN 55805 Phone: 218-249-6365 Fax: 218-249-6370 | |
Thomas George Patnoe, Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-8364 | |
Anne Nicole Normand, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-5874 |